Search

Your search keyword '"Van Zele, T."' showing total 8 results
Start Over Author "Van Zele, T." Publisher stichting nase
8 results on '"Van Zele, T."'

1. The EUFOREA pocket guide for chronic rhinosinusitis

Author

Hellings, P.W., primary, Fokkens, W.J., additional, Orlandi, R., additional, Adriaensen, G.F., additional, Alobid, I., additional, Baroody, F.M., additional, Bjermer, L., additional, Senior, B.A., additional, Cervin, A., additional, Cohen, N.A., additional, Constantinidis, J., additional, De Corso, E., additional, Desrosiers, M., additional, Diamant, Z., additional, Douglas, R.G., additional, Gane, S., additional, Gevaert, P., additional, Han, J.K., additional, Harvey, R.J., additional, Hopkins, C., additional, Kern, R.C., additional, Landis, B.N., additional, Lee, J.T., additional, Lee, S.E., additional, Leunig, A., additional, Lund, V.J., additional, Manuel-Sprekelsen, B., additional, Mullol, J., additional, Philpott, C., additional, Prokopakis, E., additional, Reitsma, S., additional, Ryan, D., additional, Salmi, S., additional, Scadding, G., additional, Schlosser, R.J., additional, Steinsvik, A., additional, Tomazic, P.V., additional, Van Staeyen, E., additional, Van Zele, T., additional, Vanderveken, O., additional, Viskens, A-S., additional, Conti, D., additional, and Wagenmann, M., additional

Published
2022
Full Text
View/download PDF

2. The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps

Author

Lien Calus, Philippe Gevaert, Lara Derycke, Hellings Pw, De Schryver E, Gabriele Holtappels, Van Zele T, Claus Bachert, and Ear, Nose and Throat

Subjects
Male, Anti-Inflammatory Agents, Administration, Oral, Omalizumab, Periostin, Antibodies, Monoclonal, Humanized, Methylprednisolone, Injections, 03 medical and health sciences, Nasal Polyps, 0302 clinical medicine, Anti-Allergic Agents, Eosinophilia, Eosinophilic, Humans, Medicine, Nasal polyps, Sinusitis, 030223 otorhinolaryngology, Randomized Controlled Trials as Topic, Rhinitis, Inflammation, Doxycycline, business.industry, General Medicine, Middle Aged, medicine.disease, Anti-Bacterial Agents, Treatment Outcome, 030228 respiratory system, Otorhinolaryngology, Chronic Disease, Immunology, Biomarker (medicine), Female, business, Cell Adhesion Molecules, Mepolizumab, Biomarkers, medicine.drug
Abstract

Background Periostin is a recently discovered biomarker for eosinophilic inflammation. Chronic rhinosinusitis with nasal polyps is a T-helper 2-skewed chronic inflammatory airway disease. Medical treatments aim to relieve symptoms and maintain clinical control by interfering with the inflammatory cascade. The effect on nasal and serum periostin levels is however yet unknown. We aimed to evaluate the effect of omalizumab, mepolizumab, methylprednisolone and doxycycline on nasal and systemic periostin expression. Methods This study is based on 3 previously published trials. Nasal and systemic periostin were assessed in CRSwNP patients, randomly assigned to receive doxycycline (n=14), methylprednisolone (n=14), mepolizumab (n=20) or omalizumab (n=15). There was a control group for each treatment scheme. Doxycycline (200 mg on the first day, followed by 100 mg once daily) and methylprednisolone (32-8 mg once daily) were administered during 20 days; mepolizumab was injected at baseline and at 4 weeks. Omalizumab was injected every 2 or 4 weeks, following the official drug leaflet. Results Methylprednisolone and omalizumab significantly reduced serum periostin levels at 4 and 8 weeks, respectively, after the start of the treatment. The effect of methylprednisolone was transient. Nasal periostin levels decreased significantly after 8 weeks of treatment with mepolizumab. The periostin expression is in accordance with the previously reported effect on the eosinophilic inflammation and clinical outcome. Conclusion All treatment options distinctly influence periostin expression, reflecting the interference with the local or systemic eosinophilic inflammatory cascade.

Published
2017

3. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps

Author

Khan, A., primary, Vandeplas, G., additional, Huynh, T.M.T., additional, Joish, V.N., additional, Mannent, L., additional, Tomassen, P., additional, Van Zele, T., additional, Cardell, L.O., additional, Arebro, J., additional, Olze, H., additional, Foerster-Ruhrmann, U., additional, Kowalski, M.L., additional, Olszewska-Ziaber, A., additional, Holtappels, G., additional, De Ruyck, N., additional, van Drunen, C., additional, Mullol, J., additional, Hellings, P.W., additional, Hox, V., additional, Toskala, E., additional, Scadding, G., additional, Lund, V.J., additional, Fokkens, W.J., additional, and Bachert, C., additional

Published
2019
Full Text
View/download PDF

4. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life

Author

Khan, A., primary, Huynh, T.M.T., additional, Vandeplas, G., additional, Joish, V.N., additional, Mannent, L.P., additional, Tomassen, P., additional, van Zele, T., additional, Cardell, L.-O., additional, Arebro, J., additional, Olze, H., additional, Forster-Ruhrmann, U., additional, Kowalski, M.L., additional, Olszewska-Ziaber, A., additional, Fokkens, W., additional, van Drunen, C., additional, Mullol, J., additional, Alobid, I., additional, Hellings, P.W., additional, Hox, V., additional, Toskala, E., additional, Scadding, G, additional, Lund, V., additional, and Bachert, C., additional

Published
2019
Full Text
View/download PDF

5. mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology

Author

Seys, S.F., primary, Bousquet, J., additional, Bachert, C., additional, Fokkens, W.J., additional, Agache, I., additional, Bernal-Sprekelsen, M., additional, Callebaut, I., additional, Cardel, L.O., additional, Carrie, S., additional, Castelnuovo, P., additional, Cathcart, R., additional, Constantinidis, J., additional, Cools, L., additional, Cornet, M., additional, Clement, G., additional, de Sousa, J.C., additional, Cox, T., additional, Doulaptsi, M., additional, Gevaert, P., additional, Hopkins, C., additional, Hox, V., additional, Hummel, T., additional, Hosemann, W., additional, Jacobs, R., additional, Jorissen, M., additional, Landis, B.N., additional, Leunig, A., additional, Lund, V.J., additional, Mullol, J., additional, Onerci, M., additional, Palkonen, S., additional, Proano, I., additional, Prokopakis, E., additional, Ryan, D., additional, Riechelmann, H., additional, Saevels, J., additional, Segboer, C., additional, Speleman, K., additional, Steinsvik, E.A., additional, Surda, P., additional, Tomazic, P.V., additional, Vanderveken, O., additional, Van Gerven, L., additional, Van Zele, T., additional, Verhaeghe, B., additional, Vierstraete, K., additional, Vlaminck, S., additional, Wilkinson, J., additional, Williams, S., additional, Pugin, B., additional, and Hellings, P.W., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results